Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Finding the Rett syndrome gene and ways to fix it
Kevin Mitchell talks with Huda Zoghbi about her work identifying the MECP2 gene, its role in the brain and therapies to address its dysfunction.
Finding the Rett syndrome gene and ways to fix it
Kevin Mitchell talks with Huda Zoghbi about her work identifying the MECP2 gene, its role in the brain and therapies to address its dysfunction.
Measuring plastic in the brain: Improving, but incomplete
Meanwhile, researchers are publishing papers without “sufficient quality control,” says analytical chemist Dušan Materić.
Measuring plastic in the brain: Improving, but incomplete
Meanwhile, researchers are publishing papers without “sufficient quality control,” says analytical chemist Dušan Materić.
Incredible shrinking grant deadlines at the BRAIN Initiative
“A month is crazy,” says one former recipient, referring to a new funding opportunity’s timeline.
Incredible shrinking grant deadlines at the BRAIN Initiative
“A month is crazy,” says one former recipient, referring to a new funding opportunity’s timeline.